Tafasitamab
Pharmaceutical drug / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Tafasitamab?
Summarize this article for a 10 year old
Tafasitamab, sold under the brand name Monjuvi, is a medication used in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).[5]
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | CD19 |
Clinical data | |
Trade names | Monjuvi, Minjuvi |
Other names | tafasitamab-cxix, MOR208, Xmab5574 |
AHFS/Drugs.com | Monograph |
License data |
|
Pregnancy category |
|
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
DrugBank | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6550H10092N1724O2048S52 |
Molar mass | 147425.93 g·mol−1 |
Tafasitamab may cause serious side effects including infusion related reactions, bone marrow suppression, infections, and harm to an unborn baby.[7] The most common side effects of tafasitamab are low blood cell counts, fatigue, diarrhea, cough, fever, limb swelling, upper respiratory infection, and decreased appetite.[7]
Tafasitamab is a humanized Fc-modified cytolytic CD19 antibody.[5][8]
Tafasitamab was approved for medical use in the United States in July 2020,[7][8][9] and in the European Union in August 2021.[6][10] The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.[11]